Download video

Michael Jain, MD, PhD, on what we're learning about 'out of specification' CAR T-cell products

12 views

OBRoncology

3 years ago

Michael Jain, MD, PhD, on what we're learning about 'out of specification' CAR T-cell products

Michael Jain, MD, PhD, on what we're learning about 'out of specification' CAR T-cell products

Michael Jain, MD, PhD, on what we're learning about 'out of specification' CAR T-cell products
2:45
Michael Jain, MD, PhD, on what we're learning about 'out of specification' CAR T-cell products
by OBRoncology
Michael Jain, MD, PhD, discusses the management of CAR T-cell therapy adverse events
2:57
Michael Jain, MD, PhD, discusses the management of CAR T-cell therapy adverse events
by OBRoncology
Michael Jain, MD, offers his opinion on off-the-shelf CAR-T cell therapy
1:10
Michael Jain, MD, offers his opinion on off-the-shelf CAR-T cell therapy
by OBRoncology
Michael Jain, MD, regarding CAR-natural killer (NK) cell therapy
0:50
Michael Jain, MD, regarding CAR-natural killer (NK) cell therapy
by OBRoncology
The use of CAR-T cell products in a real-world setting
1:02
The use of CAR-T cell products in a real-world setting
by VJHemOnc – Video Journal of Hematology \& HemOnc
Michael Jain, MD, discusses how population-based outcomes in B-cell lymphomas are changing
0:54
Michael Jain, MD, discusses how population-based outcomes in B-cell lymphomas are changing
by OBRoncology
Factors to consider when managing patients with ALL prior to CAR T-cell therapy
0:37
Factors to consider when managing patients with ALL prior to CAR T-cell therapy
by VJHemOnc – Video Journal of Hematology \& HemOnc
The importance of lymphodepletion, an undervalued component of the CAR-T therapy cycle
1:18
The importance of lymphodepletion, an undervalued component of the CAR-T therapy cycle
by VJHemOnc – Video Journal of Hematology \& HemOnc
Enhancing the long-term functionality of CAR-T cells in solid tumors
1:23
Enhancing the long-term functionality of CAR-T cells in solid tumors
by VJRegenMed
The safety and efficacy of itacitinib monotherapy for patients with low-risk GvHD
1:21
The safety and efficacy of itacitinib monotherapy for patients with low-risk GvHD
by VJHemOnc – Video Journal of Hematology \& HemOnc
An overview of CAR T-cell therapies in the treatment of patients with MCL
6:46
An overview of CAR T-cell therapies in the treatment of patients with MCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
The potentially curative role of CAR-T therapy in myeloma
1:01
The potentially curative role of CAR-T therapy in myeloma
by VJHemOnc – Video Journal of Hematology \& HemOnc
CAR T-cell therapy in the field of autoimmune disease
0:54
CAR T-cell therapy in the field of autoimmune disease
by VJHemOnc – Video Journal of Hematology \& HemOnc
Novel avenues for MM treatment: CAR T-cells, venetoclax, induction \& MRD
2:19
Novel avenues for MM treatment: CAR T-cells, venetoclax, induction \& MRD
by VJHemOnc – Video Journal of Hematology \& HemOnc
Selecting patients with multiple myeloma for CAR-T therapy
0:48
Selecting patients with multiple myeloma for CAR-T therapy
by VJHemOnc – Video Journal of Hematology \& HemOnc
Diminished chronic GvHD symptoms following anti-CD19 CAR T-cell therapy: a case study
1:57
Diminished chronic GvHD symptoms following anti-CD19 CAR T-cell therapy: a case study
by VJHemOnc – Video Journal of Hematology \& HemOnc
The importance of standardized data collection of CAR T-cells therapy
3:30
The importance of standardized data collection of CAR T-cells therapy
by VJHemOnc – Video Journal of Hematology \& HemOnc
Phase I trial of the KMT2A inhibitor KO-539 in R\/R AML
2:09
Phase I trial of the KMT2A inhibitor KO-539 in R\/R AML
by VJHemOnc – Video Journal of Hematology \& HemOnc
The importance of addressing inequalities in access to CAR-T therapy \& the role of the MDT
1:33
The importance of addressing inequalities in access to CAR-T therapy \& the role of the MDT
by VJHemOnc – Video Journal of Hematology \& HemOnc
Where are we going with CARs?
0:50
Where are we going with CARs?
by VJHemOnc – Video Journal of Hematology \& HemOnc